Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novo Nordisk Reports Encouraging Data From Hemophilia Studies

by Zacks Equity Research

Novo Nordisk (NVO) reports data on Concizumab and Refixia for the treatment of hemophilia.

Bayer-J&J Announce Positive Xarelto Data in Children with VTE

by Zacks Equity Research

Bayer's (BAYRY) Xarelto, in the phase III EINSTEIN-Jr study in pediatric patients, shows a similar low risk of VTE or blood clots compared to current standard anticoagulation therapy.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $84.86 in the latest trading session, marking a +0.98% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs

by Kinjel Shah

Pfizer (PFE) provides several regulatory/pipeline updates. CHMP gives nod to several drugs.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $86.90, marking a +1.63% move from the previous day.

Kinjel Shah headshot

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

by Kinjel Shah

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

The Zacks Analyst Blog Highlights: Chevron, Merck, Walgreens Boots, FedEx and Loews

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, Merck, Walgreens Boots, FedEx and Loews

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study

by Zacks Equity Research

AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi in first-line extensive-stage SCLC.

Mark Vickery headshot

Top Research Reports for Chevron, Merck & Walgreens Boots

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Merck (MRK) and Walgreens Boots (WBA).

The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS

Lilly's Study on Higher Doses of Trulicity Meets Endpoint

by Zacks Equity Research

Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.

FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review

by Zacks Equity Research

The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.

Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits

by Zacks Equity Research

Activist investor, Elliott Advisors, discloses a 1.1-billion-euro ($1.3 billion) stake in Bayer (BAYRY). It forms a new committee and hires U.S. lawyer Beisner to fight its glyphosate litigations.

Sejuti Banerjea headshot

Is Allergan a Good Deal for AbbVie?

by Sejuti Banerjea

AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.

Tirthankar Chakraborty headshot

4 Stocks to Make the Most of the Growing Love for Pets

by Tirthankar Chakraborty

With the U.S. pet industry poised to grow 3.9% to a record $75.4 billion this year, here are few stocks that could gain from the growing love for animals.

Merck (MRK) Stock Moves -0.33%: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $85.23, moving -0.33% from the previous trading session.

Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down

by Zacks Equity Research

Bristol-Myers (BMY) declines as it announces to sell Otezla to settle FTC concerns, while Opdivo fails in liver cancer study.

The Zacks Analyst Blog Highlights: Microsoft, Chevron, Cisco, Merck and Visa

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Microsoft, Chevron, Cisco, Merck and Visa

Neena Mishra headshot

Why These Innovative Biotech ETFs Are Soaring

by Neena Mishra

Strong M&A activity has sent shares of many small, innovative biotech companies surging

Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?

by Zacks Equity Research

Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).

Verastem Up on Positive Data From Early-Stage Copiktra Study

by Zacks Equity Research

Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

Tirthankar Chakraborty headshot

Dow on Pace for Best June: 5 Blue Chip Stocks to Buy

by Tirthankar Chakraborty

Dow eyes best June in 80 years as investors cheer the Fed's shift to a more dovish stance.

Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

by Zacks Equity Research

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

by Zacks Equity Research

Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.